GlassScriptPhysician profile
Sanjay Vinjamaram
NPI 1609010800
$3,318.75
in general payments reported to CMS, 2019-2025
47 companies · $478 in 2025
The $478 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $67.44 · 2021: $561 · 2022: $329 · 2023: $387 · 2024: $391 · 2025: $478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $341.10 | 2019-2025 | |
| Janssen Biotech, INC. | $239.85 | 2019-2024 | Darzalex, Talvey, Imbruvica |
| Ipsen Biopharmaceuticals, INC | $220.74 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $217.58 | 2019-2023 | Keytruda |
| Amgen INC. | $200.20 | 2019-2021 | |
| Celgene Corporation | $199.25 | 2019-2025 | Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $194.67 | 2019-2022 | |
| Genzyme Corporation | $137.58 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $124.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $110.44 | 2019-2025 | Enhertu, Lynparza |
| Seagen INC. | $107.56 | 2021-2023 | Adcetris |
| Daiichi Sankyo INC. | $95.26 | 2021-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $86.88 | 2019-2023 | Perjeta, Phesgo, Kadcyla |
| Takeda Pharmaceuticals U.S.A., INC. | $77.32 | 2019-2025 | Fruzaqla |
| Astellas Pharma US INC | $75.13 | 2020-2025 | Xtandi, Padcev |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Vinjamaram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.